James Phillips

Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France.

Prosonix Ltd. engages in the provision of inhaled respiratory medicines. The company was founded by Andre James Bush and David Hipkiss in 2006 and is headquartered in Oxford, the United Kingdom.

Midatech Ltd. engages in research and experimental development on biotechnology services. The company is headquartered in Abingdon, the United Kingdom.

Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom.

Insense Ltd. develops products for treatment of wounds and skin conditions. Its development activity is concentrated on dermatology products for both professional and consumer applications. The company was founded in 2001 by Paul James Davis and is headquartered in Bedford, the United Kingdom.

Aplagon Oy provides pharmaceutical discovery and development services. It develops locally acting antithrombotic products (APACs). The company was founded by Riitta Lassila and Yrjo Sakari Lassila in 2009 and is headquartered in Helsinki, Finland.

Healthcare Brands International (HBI) is a new company, established in the UK in October 2006, and participating primarily in the growing market of OTC Medicines. The company is committed to acquiring, developing and investing in differentiated healthcare products. In short it will translate innovative science into meaningful consumer brands. Funded with over £100 million of venture capital from leading international venture capital investors, the company is a team of experienced OTC blue chip business professionals with an unrivalled network of partners and contacts around the world (with particular strength in Europe). It brings core skills in consumer marketing and brand development and combine with partners providing in-market operational and regulatory expertise. It will focus on innovative products with meaningful and substantiated differentiation that meet a relevant and yet unmet or only partially met consumer need and thereby help grow the overall self-medication market.

Paion Deutschland GmbH engages in the development of pharmaceutical products. The company is headquartered in Aachen, Germany.

ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany.